An investigation on behalf of investors of Catalyst Biosciences, Inc. (NASDAQ: CBIO) shares over potential securities laws violations by Catalyst Biosciences, Inc and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Catalyst Biosciences, Inc. (NASDAQ: CBIO) concerning whether a series of statements by Catalyst Biosciences, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

South San Francisco, CA based Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications.
On June 18, 2018, Catalyst Biosciences, Inc announced that neutralizing antibodies were detected in Cohort 6 of the Phase 1/2 trial of CB 2679d/ISU304 for treatment of hemophilia B, and that Catalyst had halted the trial in order to 'conduct[] an analysis to assess the cause and impact of the antibody observations prior to dosing any further subjects in Cohort 6.'

Shares of Catalyst Biosciences, Inc. (NASDAQ: CBIO) declined from $33.81 per share on February 2018 to as low as $8.91 per share on June 18, 2018.